Melissa Johnson

564 total citations
26 papers, 228 citations indexed

About

Melissa Johnson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Melissa Johnson has authored 26 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Melissa Johnson's work include CAR-T cell therapy research (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Melissa Johnson is often cited by papers focused on CAR-T cell therapy research (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Melissa Johnson collaborates with scholars based in United States, United Kingdom and Spain. Melissa Johnson's co-authors include D M Geddes, Brian D. Flinn, G. V. Mayer, D Pavia, S W Clarke, J. E. Agnew, Robert George, Thomas R. Gadacz, Karen A. Yeh and Sallie S. Schneider and has published in prestigious journals such as The Journal of Cell Biology, Acta Biomaterialia and Thorax.

In The Last Decade

Melissa Johnson

25 papers receiving 221 citations

Peers

Countries citing papers authored by Melissa Johnson

Since Specialization

Citations

This map shows the geographic impact of Melissa Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Johnson more than expected).

Fields of papers citing papers by Melissa Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Johnson. The network helps show where Melissa Johnson may publish in the future.

Co-authorship network of co-authors of Melissa Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Johnson. A scholar is included among the top collaborators of Melissa Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Johnson. Melissa Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FAM43A coordinates mtDNA replication and mitochondrial biogenesis in response to mtDNA depletion 2025 ·The Journal of Cell Biology ·Alva G. Sainz, (unknown), Alexandra G Moyzis, (unknown), Kailash Chandra Mangalhara, Melissa Johnson, Pau B. Esparza‐Moltó, (unknown), Reuben J. Shaw, Gerald S. Shadel	2
2	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) 2024 ·Journal of Thoracic Oncology ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	0
3	FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) 2024 ·Lung Cancer ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	2
4	PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01 2024 ·Journal of Thoracic Oncology ·(unknown), (unknown), Luis Paz‐Ares, Aaron Lisberg, Melissa Johnson, M. Pérol, Danielle Carroll, Hadassah Sade, (unknown), Véronique Haddad, (unknown), Myung‐Ju Ahn	23
5	Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors 2024 ·Cancer Medicine ·Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal J. Lakhani, Hendrik‐Tobias Arkenau, Matthew D. Galsky, Emiliano Calvo, (unknown), Víctor Moreno, Omar Saavedra, Stephen J. Luen, Song Mu, (unknown), Victoria A. Chang, (unknown), Minal Barve	4
6	ALL-594 Preclinical Assessment of Dual FLT3 and BCL-2 Inhibition in Lineage Ambiguous Leukemia 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Lindsey E. Montefiori, Ilaria Iacobucci, Amit Budhraja, (unknown), (unknown), (unknown), (unknown), Melissa Johnson, Divyabharathi Chepyala, (unknown), Paul S. Mead, Joseph T. Opferman, Charles G. Mullighan	1
7	727 Interim phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Martin Gutierrez, Melissa Johnson, David Sommerhalder, Wells A. Messersmith, Haeseong Park, Muhammad Furqan, Jason Chesney, Ryan Bjordahl, Lingmin Zeng, Péter Szabó, Yu‐Waye Chu, (unknown), (unknown), Jeffrey Chou, David S. Hong	1
8	633 A phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Kim A. Reiss, Naoto T. Ueno, Yuan Yuan, Melissa Johnson, (unknown), Joseph Chao, Mathew G. Angelos, Ramona F. Swaby, Daniel Cushing, (unknown), Thomas Condamine, Débora Barton, Michael Klichinsky, Yara Abdou	5
9	634 A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Kim A. Reiss, Yuan Yuan, Naoto T. Ueno, Melissa Johnson, (unknown), Mathew G. Angelos, Joseph Chao, Saar Gill, Olga Shestova, Jonathan S. Serody, Saul J. Priceman, (unknown), Rehman Qureshi, (unknown), Daniel Cushing, Débora Barton, Michael Klichinsky, Thomas Condamine, Ramona F. Swaby, Yara Abdou	6
10	Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC) 2019 ·Clinical Trials ·Harriet M. Kluger, Sarah A. Weiss, Anthony J. Olszanski, Lynn M. Schuchter, Gerald P. Linette, Linda L. Garland, Nicholas Iannotti, Melissa Johnson, Emin Avşar, Minu K. Srivastava, Ovid Trifan, Martin J. Edelman	2
11	Abstract CT224: Phase Ib/II, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with advanced or metastatic non small cell lung cancer (NSCLC) 2019 ·Clinical Trials ·Edward B. Garon, Alexander I. Spira, Melissa Johnson, Lyudmila Bazhenova, (unknown), Albert F. Candia, Robert L. Coffman, Mary J. Janatpour, Érick Gamelin, Robert S. Janssen, Laura Q.M. Chow	1
12	Bisphenol-A in breast adipose tissue of breast cancer cases and controls 2018 ·Environmental Research ·Katherine W. Reeves, Sallie S. Schneider, Jingchuan Xue, Kurunthachalam Kannan, (unknown), Melissa Johnson, Grace Makari‐Judson, (unknown)	22
13	Novel renal biomarker evaluation for early detection of acute kidney injury after transcatheter aortic valve implantation 2018 ·Baylor University Medical Center Proceedings ·Mani Arsalan, (unknown), Róbert Farkas, Melissa Johnson, Rebeca J. Kim, Giovanni Filardo, Benjamin D. Pollock, Molly Szerlip, Michael J. Mack, Elizabeth M. Holper	5
14	Visual Expressions of Black Identity: African American and African Museum Websites 2017 ·Journal of Communication ·Melissa Johnson, (unknown)	4
15	DNA methylation in paired breast epithelial and white blood cells from women undergoing reduction mammoplasty. 2014 ·PubMed ·Susan R. Sturgeon, Kathleen F. Arcaro, Melissa Johnson, Raji Balasubramanian, Martha Zorn, D. Joseph Jerry, Sallie S. Schneider	7
16	Influence of moisture on the mechanical behavior of a natural composite 2009 ·Acta Biomaterialia ·Melissa Johnson, (unknown), Brian D. Flinn, G. V. Mayer	30
17	Asymmetry Correction in the Irradiated Breast: Outcomes of Reduction Mammaplasty and Mastopexy After Breast-Conserving Therapy 2009 ·Aesthetic Surgery Journal ·Michael S. Chin, (unknown), (unknown), (unknown), (unknown), Melissa Johnson	9
18	Leiomyosarcoma of the Colon: A Second Malignant Neoplasm after Treatment for a Wilms’ Tumor 1999 ·The American Surgeon ·Melissa Johnson, (unknown), (unknown), (unknown), Thomas R. Gadacz	10
19	Aspergillus: a rare primary organism in soft-tissue infections. 1998 ·PubMed ·Melissa Johnson, (unknown), (unknown), Karen A. Yeh	18
20	Effect of oral high frequency ventilation by jet or oscillator on minute ventilation in normal subjects. 1985 ·Thorax ·Rob George, Robbert J. de Winter, Melissa Johnson, (unknown), D M Geddes	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact